

Serum interleukin-18 and interleukin-10 levels in systemic lupus erythematosus: correlation with SLEDAI score and disease activity parameters

Sahar Abou El-Fetouh^a, Reem Hamdy A. Mohammed^c, Hanan S. Mohamad Abozaid^b

^aDepartments of Clinical Pathology,

^bRheumatology and Rehabilitation, Faculty of Medicine, Sohag University, Sohag,

^cDepartment of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence to Hanan S. Mohamad Abozaid, MD, Department Rheumatology and Rehabilitation, Faculty of Medicine, Sohag University, Sohag, Egypt
Tel: +20 115 053 2194; fax: 002-0934600526; e-mail: hanan72eg@yahoo.com

Received 10 May 2014

Accepted 29 September 2014

Egyptian Rheumatology & Rehabilitation
2014, 41:160-166

Aim

The aim of the study was to assess serum levels of interleukin (IL)-18 and IL-10 in systemic lupus erythematosus (SLE) patients and their relationship with disease activity.

Patients and methods

Thirty patients with SLE and 20 healthy controls were investigated in this study. The serum IL-18 and IL-10 levels were determined using enzyme-linked immunosorbent assay and their correlations with the disease activity were measured using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and laboratory parameters, including erythrocyte sedimentation rate, anti-ds DNA antibody, complement 3, and complement 4 levels were analyzed.

Results

The serum IL-18 and serum IL-10 levels were significantly higher (mean values 1770.2 ± 360.4 and 842.65 ± 315.37 pg/ml for IL-18 and IL-10, respectively) in SLE patients compared with the controls (110.65 ± 30.37 vs. 76 ± 14.2 pg/ml, respectively, $P < 0.001$). The increase in serum levels of IL-18 and IL-10 directly and significantly correlated with each other ($r = 0.404$, $P = 0.037$). Furthermore, such an increase in the levels of these two cytokines showed a highly significant positive correlation with the SLEDAI scores and anti-ds DNA in the studied patients ($P < 0.001$).

Conclusion

The circulating IL-18 and IL-10 concentrations were significantly elevated in SLE patients and correlated with the SLEDAI score. The study emphasized that there exists an upregulated proinflammatory as well as anti-inflammatory responses in patients with active SLE; however, the anti-inflammatory response is not enough to suppress the active disease. Identifying the exact contribution of the currently studied cytokines might provide future insights for targeted therapeutic strategies in SLE.

Keywords:

interleukin-10, interleukin-18, systemic lupus erythematosus, Systemic Lupus Erythematosus Disease Activity Index

Egypt Rheumatol Rehabil 41:160-166

© 2014 Egyptian Society for Rheumatology and Rehabilitation

1110-161X

Introduction

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of a large quantity of autoreactive antibodies and the formation of immune complexes causing tissue and organ damage [1]. The disease affects predominantly women in their reproductive years, probably due to an estrogen hormonal effect [2,3]. Aberrant production and imbalance of T-helper (Th1/Th2) cell cytokines have been implicated in the pathogenesis of autoimmunity [4]. Th1 cells produce interleukin (IL)-2, interferon γ (IFN- γ), IL-12, and IL-18, whereas Th2 cells produce IL-4, IL-5, IL-6, and IL-13 [5]. Studies in animal models of SLE suggested that in SLE there is an alteration in Th1 and/or Th2 lymphocyte function resulting in an enhanced production of cytokines that upregulate autoantibody production by B cells. Accordingly, in murine models of

SLE, an altered production of both Th1 (such as IFN- γ , IL-18, and IL-2) and Th2 (such as IL-4 and IL-10) cytokines has been reported [6].

From Th1 cells, we have selected IL-18 as a proinflammatory cytokine, predominantly released by antigen-presenting cells such as macrophages and dendritic cells. IL-18 acts as a Th1 cytokine, as it promotes both proliferation of Th1 lymphocytes and IFN- γ production by these cells [7]. IL-18 shares functional similarities with IL-12, which induces the production of IL-18 by activation of natural killer (NK) cells and cytotoxic T lymphocytes [8].

Evidence is now accumulating to suggest the potential role of IL-18 in SLE; IL-18 may prove to be an important target for developing new drugs and treatment in SLE [9], as the primary function of IL-18 involves

the induction of IFN- γ and tumor necrosis factor α (TNF- α) in T cells and NK cells, the upregulation of Th1 cytokines, including IL-2, granulocyte-macrophage colony stimulating factor, and IFN- γ , and stimulation of proliferation of activated T cells [10]. IL-18 has been found to be elevated in serum of lupus patients and to correlate with disease activity. It has been postulated that IL-18 may act together with TNF- α and IL-1 to mediate the inflammatory mechanism in SLE patients [11]. It accelerates spontaneous lupus disease with characteristic glomerulonephritis and vasculitis. This is further exacerbated by the synergistic action of IL-12 and IL-18, a combination known to promote Th1 cell development including reciprocal enhancement of their receptor expression. In contrast, several studies have reached the opposite conclusions that the levels of serum IL-18 are irrelevant to disease activity and kidney involvement [7,12]. Thus, the functions of IL-18 in the pathogenesis of Lupus Nephritis (LN) are still debated.

However, from the Th2 cells, we have selected IL-10 prototype to study, as IL-10 is a key immune-regulatory cytokine produced by a multiplicity of immune cells including monocytes, macrophages, mast cells, NK cells, eosinophils, and neutrophils and by adaptive immune cells such as Th1, Th2, and CD8⁺ T and B cells [13,14]. IL-10 has been shown to exert a potent suppressor effect on macrophage activity, in addition to its recognized direct inhibitory effects on the proliferation of CD4⁺ T cells. It was also found to suppress the production of proinflammatory cytokines such as IL-2, IFN- γ , IL-4, IL-5, and TNF- α . In contrast, IL-10 has been shown to stimulate the growth of mast cells, B and Th2 lymphocytes and promote adaptive immunity [15] and type 2 cytokine pattern by inhibiting the IFN- γ production of T lymphocytes [16–18]. In early lupus, IL-10 was found to play a downregulatory role, whereas at later phases of disease excessive production of IL-10 might result in enhanced autoantibody production and subsequent formation of pathogenic autoantibody–antigen complexes as has been illustrated in in-vitro studies that anti-IL-10 antibodies could markedly inhibit immunoglobulin production by SLE peripheral blood mononuclear cells, which corroborated the role of IL-10 in mediating autoantibody production [19,20].

This study aimed to assess serum levels of IL-18 and IL-10 in SLE and their relationship with disease activity, as it might provide future insights for targeted therapeutic strategies in SLE.

Patients and methods

Patients were selected from outpatient clinics of the Rheumatology Department of Faculty of Medicine,

Sohag University, between December 2011 and December 2012. The study included 30 patients (female/male = 27/3) with the established diagnosis of SLE classification performed according to the American College of Rheumatology criteria [21]. Their ages ranged from 25 to 44 years. Twenty age-matched and sex-matched normal healthy individuals (female/male = 17/3) were included as the control group. Their ages ranged from 23 to 42 years with a mean of 32.67 ± 2.1 years. Informed consents were taken from the participants and the study was approved by the ethics committee of the research organization.

The study population was subjected to the following clinical and investigational work-up:

Full history taking including age, sex, disease duration as well as swollen and tender joint counts of the patients was performed; chest radiography and echocardiography were performed. Clinical assessment of the disease activity was performed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score. A SLEDAI score of more than 6 was considered active disease [22].

Laboratory work-up included routine laboratory survey with complete blood picture (Coulter STKS Hematology Flow Cytometer; Block Scientific Inc., Bohemia, New York, USA); erythrocyte sedimentation rate (ESR) was expressed in mm/h. The C-reactive protein (CRP) concentration was determined by immunonephelometry methods (Orion Diagnostica, Finland); concentrations of 6 mg/l were considered positive for CRP [23,24]. The serum levels of complement 3 (C3) and complement 4 (C4) were quantitatively measured in all samples by means of immune-turbidimetry with the Turbid Time System (Dade Behring, USA) according to the manufacturer instructions and expressed in terms of mg/dl. Antinuclear antibody (ANA) and antibodies to double-stranded DNA (anti-DNA) were measured using indirect immunofluorescence. Blood samples from SLE patients and controls were centrifuged and sera were obtained for immediate carry on of routine laboratory work-up. The remaining sera were stored frozen in aliquots at -20°C for the subsequent assays; urine analysis was performed. Patients with lupus nephritis were defined by persistent proteinuria greater than 0.5 g/24 h or by the presence of cellular casts or persistent hematuria; renal biopsy was not performed.

Determination of serum IL-18 was performed using an enzyme-linked immunosorbent assay (ELISA) kit (Biosource International Inc., Camarillo, California, USA). Samples and standards of human

IL-18 (Hu IL-18) and controls were pipetted into these wells and incubated for 1 h. Thereafter, a monoclonal antibody specific for Hu IL-18 was added and incubated for 1 h. Hu IL-18 was captured and immobilized onto the plate. After washing, a horseradish peroxidase (HRP)-conjugated anti-Hu IL-18 antibody was pipetted into the wells and incubated for 1 h. The HRP activity was detected by addition of trimethylbenzidine chromogenic reagent. Substrate and the color produced was proportional to the quantity of Hu IL-18 contained in the sample. Finally, the reaction was stopped with the addition of stop solution, which terminates the HRP-catalyzed reaction. The absorbance of each well was measured at 450 nm using a microtiter plate reader. A calibration curve was plotted and IL-18 concentration in samples was determined by interpolation from the calibration curve. The normal values were set according to the calibration curve based on manufacturer's instructions and they ranged from 36.05 to 257.75 pg/ml with a cutoff level of 259.41 pg/ml. Determination of serum IL-10 was performed using ELISA kits (Biosource International Inc.), following the manufacturers' instructions; the samples, standard, and controls were added to wells followed by the incubation buffer. After incubation, biotin-conjugated anti-IL-10 antibody was added to each well. After 2 h of incubation, streptavidin-HRP working conjugate was added; finally, chromogen was added followed by the stop solution then absorbance was read at 450 nm. The normal values for serum IL-10 ranged between 7.8 and 500 pg/ml.

Statistical analysis

Statistical analysis was performed using SPSS program (version 15; SPSS Inc., Chicago, Illinois, USA). Data were presented as number (%), with mean \pm SD. The Mann-Whitney *U*-test was used for the analysis of two quantitative data. Spearman's correlation was used for detection of the relationship between two variables. The differences between categorical variables were investigated using the χ^2 -test. *P* value was considered significant if less than 0.05.

Results

The study included 30 patients with the diagnosis of SLE and 20 healthy control individuals with the mean age 34.62 ± 4.3 and 32.67 ± 2.1 years, respectively. The mean duration of the disease in the studied patients was 5.6 ± 3.4 years. Patients were on the following treatments: prednisolone 10–50 mg/day (mean 25.20 ± 5.75 mg/day), hydroxychloroquine 200–400 mg/day (mean 280 ± 172.76 mg/day), and

azathioprine 50–150 mg (mean 115.45 ± 25.59 mg/day) daily in combination. The clinical and descriptive data of SLE patients and statistical comparison of laboratory work-up between the studied SLE patients and healthy controls are shown in Tables 1–3. The study found that ANA was positive in 40% of the patients, whereas anti-ds DNA was positive in 30%. The study reported a SLEDAI score that ranged from 1 to 44 with a mean \pm SD 23.69 ± 18 in the studied patients with SLE; 53.3% of the studied SLE patients had a SLEDAI score of at least 6) who were considered as the active disease group (Table 4). The number of patients with lupus nephritis was four (13%) and vasculitis was five (17%), which was too small number to give statistical significance, if wanted to differentiate the patients according to each of them. Surveying serological biomarkers of inflammation in the examined SLE patients results illustrated a highly significant decrease in the mean value of serum C3 and C4 level in the studied SLE patient compared with controls ($P = 0.000$), and such decline in complement levels significantly correlated with an observable increase in the SLEDAI score values ($r = -0.431$, $P = 0.003$, and $r = -0.68$, $P = 0.001$, respectively) (Table 5).

Table 1 Descriptive data of the studied patients with systemic lupus erythematosus

Patients (<i>n</i> = 30)	Range	Mean \pm SD
Age (years)	25–44	34.26 ± 4.3
Disease duration (years)	2–9	5.6 ± 3.4
SLEDAI	1–44	23.69 ± 18

SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

Table 2 Cumulative clinical manifestations of the patients studied (*n* = 30)

Clinical manifestations	<i>n</i> (%)
Arthritis	21 (70)
Myositis	4 (13)
Facial rash	24 (80)
Raynaud's phenomena	5 (17)
Discoid lupus	0 (0)
Mucosal ulceration	5 (17)
photosensitivity	7 (23)
Alopecia	19 (63)
Hemolytic anemia	7 (23)
Leukopenia ($<4 \times 10^9/l$)	6 (20)
Thrombocytopenia ($<100 \times 10^9/l$)	13 (43)
Lymphopenia ($<1.5 \times 10^9/l$)	2 (7)
Lymphadenopathy	0 (0)
Seizure	0 (0)
Psychosis	4 (13)
Myelopathy	13 (43)
Neuropathy (peripheral or cranial)	3 (10)
Optic neuritis	0 (0)
Renal	4 (13)
Serositis	5 (16)

Table 3 Statistical comparison of laboratory work-up between the studied systemic lupus erythematosus patients and healthy controls

Parameters	SLE patients (n = 30)	Control (n = 20)	P value
HGB (g/dl)	11.5 ± 1.8	12.6 ± 2.3	NS
TLC (10 ³ /mm ³)	4.6 ± 1.3	4.8 ± 1.3	NS
Platelets	280 ± 120	350 ± 130	NS
ESR (mm/1st h)	112.19 ± 12.30	7.1 ± 2.96	0.006**
Urea (mg/dl)	29.90 ± 7.59	21.17 ± 1.73	NS
Creatinine (mg/dl)	0.97 ± 0.13	0.87 ± 0.07	NS
CRP (mg/l)	42.65 ± 8.59	3.7 ± 11.8	0.000**
C3 (mg/dl)	50 ± 9.1	126.96 ± 12.1	0.000**
C4 (mg/dl)	14 ± 3.1	36 ± 6.1	0.001**
Positive anti-ds DNA	9 (30)	0 (0)	0.04*
Positive ANA	12 (40)	1 (5)	0.05*
Serum IL-18 (pg/ml)	3131.2 ± 1211.41	110.65 ± 30.37	0.000**
Serum IL-10 (pg/ml)	120 ± 27.2	76 ± 14.2	0.000**

Data are expressed as mean ± SD or n (%); ANA, antinuclear antibody; anti-ds DNA, antibodies to double-stranded DNA; C3, complement 3; C4, complement 4; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HGB, hemoglobin; IL, interleukin; SLE, systemic lupus erythematosus; TLC, total leukocyte count; *Significant ($P < 0.05$); **Highly significant ($P < 0.001$).

Table 4 Results of laboratory investigations for active and inactive systemic lupus erythematosus patients

Parameters	Active (n = 14)	Inactive (n = 16)	P value
HGB (g/dl)	8.01 ± 1.74	11.7 ± 0.5	0.05*
TLC (10 ³ /mm ³)	4.5 ± 1.3	4.8 ± 1.3	NS
Platelets	265.36 ± 89.49	36319.68	0.018*
ESR (mm/1st h)	105.83 ± 45.68	58.25 ± 43.03	0.006**
SLEDAI	26.67 ± 5.02	9.75 ± 1.91	NS
CRP (mg/l)	38.65 ± 9.59	24.7 ± 11.8	0.05*
C3 (mg/dl)	22.65 ± 8.59	26 ± 12.1	NS
C4 (mg/dl)	10 ± 9.1	16 ± 6.1	NS
Anti-ds DNA	9 (100)	0 (0.0)	0.000**
Positive ANA	10 (40)	2 (12.5)	0.001**
IL-18 (pg/ml)	1770.2 ± 360.4	842.65 ± 315.37	0.001*
IL-10 (pg/ml)	80 ± 18.2	41 ± 6.7	0.001**

Data are expressed as mean ± SD or n (%); Anti-ds DNA, antibodies to double-stranded DNA; C3, complement 3; C4, complement 4; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HGB, hemoglobin; IL, interleukin; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; TLC, total leukocyte count; *Significant; **Highly significant.

Table 5 The clinically relevant correlations reported in the study

Parameters	IL-18	IL-10
SLEDAI	$r = 0.556$ $P < 0.05$	$r = 0.551$ $P < 0.05$
CRP	$r = 0.48$ $P < 0.05$	$r = 0.44$ $P < 0.05$
ANA positive	$r = 0.41$ $P < 0.05$	$r = 0.72$ $P < 0.05$
Anti-ds DNA	$r = 0.58$ $P < 0.05$	$r = 0.55$ $P < 0.05$
C3	$r = 0.25$ $P > 0.05$	$r = 0.25$ $P > 0.05$
C4	$r = 0.24$ $P > 0.05$	$r = 0.74$ $P < 0.05$

ANA, antinuclear antibody; anti-ds DNA, antibodies to double-stranded DNA; C3, complement 3; C4, complement 4; CRP, C-reactive protein; IL, interleukin; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

Levels of serum interleukin-18 in the studied population

The study found significantly higher levels of serum IL-18 (mean ± SD 3131.2 ± 1211.41 pg/ml) in SLE patients compared with the reported values in the matching control group (mean ± SD 110.65 ± 30.37 pg/ml, $P < 0.001$) (Table 3). A statistically significant correlation was reported between serum IL-18 levels and the total SLEDAI score in all SLE patients ($r = 0.556$, $P = 0.003$). Moreover, a significant correlation was found between serum IL-18 levels and seropositivity to ANA as well as anti-ds DNA in the studied patients (for IL-18 and ANA $r = 0.412$, and for IL-18 and anti-DNA $r = 0.584$, $P = 0.001$). The serum levels of IL-18 did not show significant variations with respect to sex (female 2113.00 ± 53.31 pg/ml and male 2002.56 ± 48.19 pg/ml, $P = 0.08$), age, or disease duration ($r = 0.24$, 0.123 , respectively, $P > 0.05$) in the studied SLE patients. Negative correlations were found between serum IL-18 and C3 and C4 ($r = -0.253$ and -0.241 , respectively, $P > 0.05$), although they did not reach statistical significance. The study also could not detect any significant correlation between the increase in serum levels of IL-18 and ESR in the studied patients (Table 5).

Levels of serum interleukin-10 in the studied population

Results of this study showed that the serum levels were significantly higher in patients (120 ± 27.2 pg/ml) compared with their matching healthy controls (76 ± 14.2 pg/ml, $P < 0.001$) (Table 3). Similarly, serum levels of IL-10 similar to those of IL-18 did not show significant variations with respect to sex (male 96 ± 23.31 pg/ml and female 72.56 ± 18.19 pg/ml, $P = 0.21$), patient's age, or disease duration ($r = 0.25$, 0.123 , respectively, $P > 0.05$). In contrast, a significant correlation was found between serum IL-10 and the SLEDAI score in all SLE patients ($r = 0.551$, $P < 0.01$). Moreover, results illustrated a significant positive correlation between serum levels of IL-10 and C4 ($r = 0.741$, $P < 0.05$) as well as with seropositivity to ANA and anti-ds DNA in the studied SLE patients ($r = 0.72$, $r = 0.584$, respectively, $P = 0.001$). Similarly, the current study found a significant positive correlation between serum IL-18 concentration and serum levels of IL-10 ($r = 0.404$, $P = 0.037$). The increase in serum levels of IL-18 and IL-10 positively correlated with the values of CRP in patients with active disease ($r = 0.48$ and 0.44 , respectively, $P < 0.05$).

In contrast, the study did not find any significant correlations between serum IL-10 and each of the following: C3 levels or ESR ($r = 0.25$ and -0.208 , respectively, $P > 0.05$) (Table 5).

Discussion

SLE is classified as an autoantibody-mediated immune complex disease. The role of Th2 cytokines in disease pathogenesis has always been dominant and attracted attention as a potential target for therapeutic interventions [25–33]. The current research aimed to assess the relationship between SLE disease activity in a population of Egyptian patients in terms of the SLEDAI score and two of the most pathogenetically significant cytokines that have attracted researchers, IL-18 and IL-10; in addition, the study tried to explore the possible influence of the serologic profile and the results of the inflammatory biomarkers on the level of these two cytokines. The study included 30 patients with SLE; over 50% of the patients had a clinically significant SLEDAI score greater than 6 manifesting significantly active SLE, despite being on multiple Disease Modifying Anti Rheumatic Drugs (DMARDs). The study found that ANA was positive in 40% of the patients, whereas anti-ds DNA was positive in 30%. This might be attributed to the influence of the immune-modulatory effects of drug combinations used in the studied patients. Regarding the surveyed cytokines, for the first cytokine, which is IL-18, the study found significant elevation of serum IL-18 in all SLE patients included compared with the control group, and this elevation correlated significantly with clinically active disease illustrated in terms of SLEDAI score. Elevated levels of IL-18 in SLE patients have been reported in several late studies particularly in patients with clinically active systemic illness [34–37]. Results of the current study are in agreement with those obtained by Esfandiari *et al.* [33], Wong *et al.* [37], as well as Amerio *et al.* [38], where the researchers illustrated a significant elevation in IL-18 concentration in patients with SLE compared with controls ($P < 0.001$), which correlated with the SLEDAI activity score in their patients population [39]. In contrast to these studies, Robak *et al.* [7] did not find significant differences in the levels of IL-18 between active and inactive SLE in their work, which might have been explained by the fact that SLE is a heterogeneous disease in which variability in the mean levels of certain cytokines is expected with different phases of disease activity as well as with therapeutic interventions. Furthermore, cytokine levels in the plasma might not always reflect the locally high concentration produced in lymphoid tissues, as cytokines in the plasma might be bound to proteins or form complexes with soluble receptors or autoantibodies, which might affect their detection [7,40]. Age and sex were shown to have no significant influence on the serum levels of IL-18 in SLE patients [34,41], which is consistent with results of this study.

The second cytokine assessed in the current research was IL-10. The immune-regulatory effects of IL-10

in SLE have been successively reported in a variety of human as well as experimental studies, some of which illustrated that continuous administration of anti-IL-10 has been reported to delay the onset of lupus reflecting a relatively protective immune-regulatory effect of this cytokine against the induction and development of lupus-like disease in mice. Other studies showed that peripheral blood mononuclear cells from active SLE patients were found to spontaneously produce high amounts of IL-10 *in vitro*; furthermore, antagonism to the biologic functions of IL-10 was found to decrease immunoglobulin and anti-DNA production by SLE lymphocytes both *in vivo* and *in vitro* [42–45]. In contrast, Chun *et al.* [46] found a positive correlation between circulating levels of IL-10 and the titer of anti-ds DNA antibodies as a marker of disease activity in humans. Ishida *et al.* [43] and Chun *et al.* [46] demonstrated that serum IL-10 levels are higher in SLE patients than in controls and showed a positive correlation with SLEDAI and anti-ds DNA and negative correlation with C3, C4, and peripheral lymphocyte counts. These findings in combination with current data where serum IL-10 levels were significantly elevated in the studied population of SLE patients indicated that IL-10 might be part of the regulatory response that was not fully capable of compensating for the prevailing proinflammatory response. This suggests that IL-10 might play an important role in the pathogenesis of SLE. There were significant associations between IL-10 and disease activity score, anti-DNA antibodies and C4 in our population of SLE patients ($P < 0.05$); yet, serum IL-10 levels showed a negative correlation with C3 levels. These findings were similar with the results reported by Houssiau *et al.* [44], El-Sayed *et al.* [47], and Park *et al.* [48], where they showed that IL-10 positively correlated with SLEDAI and anti-DNA antibodies but negatively correlated with C3 levels; however, the authors did not comment on C4 titers in these studies. In contrast, Llorente *et al.* [45] in their study could not find any significant association between IL-10 and disease activity in SLE; such discrepancy might be attributed to the difference in the assessment technique as the current study measured IL-10 in the sera of patients, whereas in the study by Llorente and colleagues, the authors studied its concentration in peripheral mononuclear cells cultures after 24 h. IL-10 plays a role in inhibition of proinflammatory cytokines; despite this, it appears that, in patients with active disease as reported in the current study, the increase in serum IL-10 failed to inhibit production of the proinflammatory cytokine IL-18. The authors hypothesize that, during an immune response, both IL-10 and IL-18 are cytokines that need to be coexpressed and it is the balance between the inflammatory and anti-inflammatory cytokines that

aborts autoimmunity [46–50]. This explanation is supported by previous studies that reported that IL-10 and IL-18 synergize to enhance NK cell proliferation, cytotoxicity, and IFN- γ production. In addition, IL-10 may synergize with IL-18 to potentiate Th1 responses at a lower intensity than induced by IL-12 and IL-18, to dampen the inflammatory response without abolishing it [50,51].

Conclusion

The circulating IL-18 and IL-10 concentrations were significantly elevated in the sera of SLE patients and correlated with the SLEDAI score. The study emphasizes that there exists an upregulated proinflammatory as well as anti-inflammatory responses in patients with active SLE; however, the anti-inflammatory response is not enough to suppress the active disease. Further studies on larger populations are recommended for better understanding of the precise mechanism through which IL-10 and IL-18 are involved in the pathogenesis of SLE; in addition, the relationship of these two cytokines to specific organ damage in SLE needs to be addressed specifically in future studies. Identifying the exact contribution of the currently studied cytokines might provide future insights for targeted therapeutic strategies in SLE.

Study limitations

- (1) SLE is a disease of the female population, which contributes to some sort of statistical bias with small sample sizes in trials to assess the influence of sex on the perceived values of the studied cytokines.
- (2) The study did not assess the relationship between the studied cytokines and specific organ disease in SLE patients; however, it was indirectly studied in terms of SLEDAI score.
- (3) The study did not assess the possible associations between the titers of ANA and anti-DNA to the variations in the levels of the studied cytokines in SLE patients included due to technical and financial issues.

Acknowledgements

Conflicts of interest

Sahar Abou El-Fetouh Hanan S Abozaid. Mohammed received financial support from the Department of Medical Research in Sohag University Hospital, Sohag University, for this research. For Reem M Hamdy, there are no conflicts of interest.

References

- 1 Manson JJ, Rahman A. Systemic lupus erythematosus. *Orphanet J Rare Dis* 2006; **1**:6.
- 2 Lee HM, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. *J Biomed Biotechnol* 2010; **2010**:676284.
- 3 Sekigawa I, Fujishiro M, Yamaguchi A, *et al.* A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. *Clin Exp Rheumatol* 2010; **28**:419–423.
- 4 Viillard J, Pellegrin J, Ranchin V, *et al.* Th1 (IL-2, interferon-gamma) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). *Clin Exp Immunol* 1999; **115**:189–195.
- 5 Pan HF, Ye DQ, Li XP. Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. *Nat Clin Pract Rheumatol* 2008; **4**:352–353.
- 6 Csizsar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E. Increased interferon-gamma (IFN- γ), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). *Clin Exp Immunol* 2000; **122**:464–470.
- 7 Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, Stepień H. Proinflammatory interferon-gamma – inducing monokines (interleukin-12, interleukin-18, interleukin-15) – serum profile in patients with systemic lupus erythematosus. *Eur Cytokine Netw* 2002; **13**:364–368.
- 8 Fehniger TA, Shah MH, Turner MJ, *et al.* Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. *J Immunol* 1999; **162**:4511–4520.
- 9 Xu W-D, Pan H-F, Ye D-Q. Association of interleukin-18 and systemic lupus erythematosus. *Rheumatol Int* 2013; **33**:3055–3057.
- 10 Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H. Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. *Cell Immunol* 1996; **173**:230–235.
- 11 Wong CK, Ho CY, Li EK, Tam LS, Lam CW. Elevated production of interleukin-18 is associated with renal disease in patients with systemic lupus erythematosus. *Clin Exp Immunol* 2002; **130**:345–351.
- 12 Tokano Y, Suzuki J, Amano H, Nozawa K, Morimoto S, Hashimoto H. Increased levels of interleukin-18 in patients with systemic lupus erythematosus: comment on the article by Shibatomi *et al.* *Arthritis Rheum* 2002; **46**:1410–1411. author reply 1411–1412.
- 13 Rhodes KA, Andrew EM, Newton DJ, Tramonti D, Carding SR. A subset of IL-10-producing gammadelta T cells protect the liver from Listeria-elicited, CD8(+) T cell-mediated injury. *Eur J Immunol* 2008; **38**:2274–2283.
- 14 Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. *J Immunol* 2009; **182**:7459–7472.
- 15 Lacki JK, Leszczynski P, Kelemen J, Muller W, Mackiewicz SH. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. *J Med* 1997; **28**:99–107.
- 16 Romagnani S. Biology of human TH1 and TH2 cells. *J Clin Immunol* 1995; **15**:121–129.
- 17 Joss A, Akdis M, Faith A, Blaser K, Akdis CA. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. *Eur J Immunol* 2000; **30**:1683–1690.
- 18 Schuetze N, Schoeneberger S, Mueller U, Freudenberg MA, Alber G, Straubinger RK. IL-12 family members: differential kinetics of their TLR4-mediated induction by *Salmonella enteritidis* and the impact of IL-10 in bone marrow-derived macrophages. *Int Immunol* 2005; **17**:649–659.
- 19 Yin Z, Bahtiyar G, Zhang N, *et al.* IL-10 regulates murine lupus. *J Immunol* 2002; **169**:2148–2155.
- 20 Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. *Arthritis Rheum* 2000; **43**:1976–1981.
- 21 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; **40**:1725.
- 22 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. *Arthritis Rheum* 1992; **35**:630–640.
- 23 Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. *Cleve Clin J Med* 1989; **56**:126–130.

- 24 Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. *Scand J Immunol* 1995; **41**:534–538.
- 25 Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. *J Exp Med* 1993; **177**:1367–1381.
- 26 Strand V. Lessons learned from clinical trials in SLE. *Autoimmun Rev* 2007; **6**:209–214.
- 27 Arason GJ, Steinsson K, Kolka R, Vikingsdottir T, D'Ambrogio MS, Valdimarsson H. Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation. *Rheumatology (Oxford)* 2004; **43**:783–789.
- 28 Sturfelt G, Truedsson L. Complement and its breakdown products in SLE. *Rheumatology (Oxford)* 2005; **44**:1227–1232.
- 29 Gaipl US, Munoz LE, Grossmayer G, *et al.* Clearance deficiency and systemic lupus erythematosus (SLE). *J Autoimmun* 2007; **28**:114–121.
- 30 Tyrrell-Price J, Lydyard PM, Isenberg DA. The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. *Clin Exp Immunol* 2001; **124**:118–125.
- 31 Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. *J Allergy Clin Immunol* 1999; **103**:11–24.
- 32 Park MC, Park YB, Lee SK. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. *Clin Rheumatol* 2004; **23**:225–229.
- 33 Esfandiari E, McInnes IB, Lindop G, *et al.* A proinflammatory role of IL-18 in the development of spontaneous autoimmune disease. *J Immunol* 2001; **167**:5338–5347.
- 34 Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. *Clin Exp Immunol* 2004; **138**:171–178.
- 35 Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. *Arthritis Rheum* 2008; **58**:251–262.
- 36 Chen DY, Hsieh CW, Chen KS, Chen YM, Lin FJ, Lan JL. Association of interleukin-18 promoter polymorphisms with WHO pathological classes and serum IL-18 levels in Chinese patients with lupus nephritis. *Lupus* 2009; **18**:29–37.
- 37 Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. *Lupus* 2000; **9**:589–593.
- 38 Amerio P, Frezzolini A, Abeni D, *et al.* Increased IL-18 in patients with systemic lupus erythematosus: relations with Th-1, Th-2, pro-inflammatory cytokines and disease activity. IL-18 is a marker of disease activity but does not correlate with pro-inflammatory cytokines. *Clin Exp Rheumatol* 2002; **20**:535–538.
- 39 Mohsen MA, Abdel Karim SA, Abbas TM, Amin M. Serum interleukin-18 levels in patients with systemic lupus erythematosus: relation with disease activity and lupus nephritis. *Egypt Rheumatol* 2013; **35**:45–51.
- 40 Horwitz D, Stohl W, Gray J. T lymphocytes, natural killer cells, cytokines, and immune regulation. *Dubois' Lupus Erythematosus* 1997; **151**:155.
- 41 Andoh T, Kishi H, Motoki K, Nakanishi K, Kuraishi Y, Muraguchi A. Protective effect of IL-18 on kainate- and IL-1 beta-induced cerebellar ataxia in mice. *J Immunol* 2008; **180**:2322–2328.
- 42 Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Stoeber ZM. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. *J Autoimmun* 2010; **34**:121–126.
- 43 Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. *J Exp Med* 1994; **179**:305–310.
- 44 Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M, Devogelaer JP, Renaud JC. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. *Lupus* 1995; **4**:393–395.
- 45 Llorente L, Richaud-Patin Y, Garcia-Padilla C, *et al.* Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. *Arthritis Rheum* 2000; **43**:1790–1800.
- 46 Chun HY, Chung JW, Kim HA, *et al.* Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. *J Clin Immunol* 2007; **27**:461–466.
- 47 El-Sayed M, Nofal E, Al Mokadem S, Al Makhzangy I, Gaballah H, Akl H. Correlative study of serum Th1/Th2 cytokines levels in patients with systemic lupus erythematosus with SLEDAI. *Egypt Dermatol Online J* 2008; **4**:3–19.
- 48 Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. *Clin Exp Rheumatol* 1998; **16**:283–288.
- 49 Ling GS, Cook HT, Botto M, Lau YL, Huang FP. An essential protective role of IL-10 in the immunological mechanism underlying resistance vs. susceptibility to lupus induction by dendritic cells and dying cells. *Rheumatology (Oxford)* 2011; **50**:1773–1784.
- 50 Zediak VP, Hunter CA. IL-10 fails to inhibit the production of IL-18 in response to inflammatory stimuli. *Cytokine* 2003; **21**:84–90.
- 51 Yasutomo K. Pathological lymphocyte activation by defective clearance of self-ligands in systemic lupus erythematosus. *Rheumatology (Oxford)* 2003; **42**:214–222.